SEARCH

SEARCH BY CITATION

REFERENCES

  • Akey JM, Zhang G, Zhang K, Jin L, Shriver MD (2002) Interrogating a high-density SNP map for signatures of natural selection. Genome Res 12:18051814.
  • Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A COMBINE Study Research Group (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:20032017.
  • Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL (2001) A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276:31303137.
  • Beyer A, Koch T, Schroder H, Schulz S, Hollt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89:553560.
  • Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95:96089613.
  • Bouza C, Angeles M, Munoz A, Amate JM (2005) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99:811828.
  • Covault C, Gelernter J, Hesselbrock V, Nellissery M, Kranzler HR (2004) Allelic and haplotypic association of GABRA2 with alcohol dependence. Am J Med Genet 129B:104109.
  • Derogatis LR, Melisaratos N (1983) The brief symptom inventory: an introductory report. Psychol Med 13:595605.
  • Edenberg HJ, Dick DM, Xuei X, Tian H, Almasy L, Bauer LO, Crowe RR, Goate A, Hesselbrock V, Jones K, Kwon J, Li TK, Nurnberger JI Jr., O'Connor SJ, Reich T, Rice J, Schuckit MA, Porjesz B, Foroud T, Begleiter H (2004) Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet 74:705714.
  • Feinn R, Nellissery M, Kranzler HR (2005) Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 133:7984.
  • First MB, Gibbon M, Spitzer RL, Williams JBW (1996) User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders—Research Version. Biometrics Research, New York.
  • Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, Maany I, Neiderhiser D, Nocks JJ, Shaw S (1986) Disulfiram treatment of alcoholism. A veterans administration cooperative study. JAMA 256:14491455.
  • Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT (1999) Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 281:13181325.
  • Gelernter J, Kranzler HK (2000) Variant detection at the delta opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. Hum Genet 107:8688.
  • Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O'Malley SS (1996) Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 64:10441053.
  • Kranzler HR, Abu-Hasaballah K, Tennen H, Feinn R, Young K (2004) Using daily interactive voice response technology to measure drinking and related behaviors in a pharmacotherapy study. Alcohol Clin Exp Res 28:10601064.
  • Kranzler HR, Tennen H (2004) How to measure relapse in humans, in Drugs for Relapse Prevention of Alcoholism (SpanagelR, MannK eds), pp 2339. Birkhauser Verlag, Basel.
  • Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25:13351341.
  • Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study 425 Group (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345:17341739.
  • Lappalainen J, Krupitsky E, Remizov M, Pchelina S, Taraskina A, Zvartau E, Somberg LK, Covault J, Kranzler HR, Krystal JH, Gelernter J (2005) Association between alcoholism and GABRA2 in a Russian population. Alcohol Clin Exp Res 29:493498.
  • Lee MC, Wagner HN Jr., Tanada S, Frost JJ, Bice AN, Dannals RF (1988) Duration of occupancy of opiate receptors by naltrexone. J Nuclear Med 29:12071211.
  • Lesscher HM, Bailey A, Burbach JP, Van Ree JM, Kitchen I, Gerrits MA (2003) Receptor-selective changes in mu-, delta- and kappa-opioid receptors after chronic naltrexone treatment in mice. Eur J Neurosci 17:10061012.
  • Liu K, Muse SV (2005) PowerMarker: integrated analysis environment for genetic marker data. Bioinformatics 21:21282129.
  • Luo X, Kranzler HR, Zhao H, Gelernter J (2003) Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet (Neuropsychiatr Genet) 120B:97108.
  • Luo X, Kranzler HR, Zuo L, Lappalainen J, Yang BZ, Gelernter J (2006) ADH4 gene variation is associated with alcohol and drug dependence in European Americans: results from HWD tests and case-control association studies. Neuropsychopharmacology 31:10851095.
  • Luo X, Kranzler HR, Zuo L, Wang S, Blumberg HP, Gelernter J (2005) CHRM2 gene predisposes to alcohol dependence, drug dependence, and affective disorders: results from an extended case-control structured association study. Hum Mol Genet 14:24212434.
  • Mark TL, Kranzler HR, Song X, Bransberger P, Poole V, Crosse S (2003) Physicians' opinions about medications to treat alcoholism. Addiction 98:617626.
  • McCaul ME, Wand GS, Kim YK, Bencherif B, Dannals RF, Frost JJ (2003) Naltrexone effects on mu- and delta-opioid receptor availability in alcohol dependence. Alcohol Clin Exp Res 27 (5 suppl): 21A.
  • Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10:258268.
  • Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:15461552.
  • Petrakis IL, Leslie D, Rosenheck R (2003) Use of naltrexone in the treatment of alcoholism nationally in the department of veterans affairs. Alcohol Clin Exp Res 27:17801784.
  • Rubio G, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J, Palomo T (2005) Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol 40:227233.
  • Shi MM, Myrand SP, Bleavins MR, De La Iglesia FA (1999) High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes. Mol Pathol 52:295299.
  • Srisurapanont M, Jarusuraisin N (2005) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. (1):CD001867.
  • Streeton C, Whelan G (2001) Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. [Journal Article. Meta-Analysis]. Alcohol Alcohol 36:544552.
  • Volpicelli JR, Clay KL, Watson NT, O'Brien CP (1995) Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry 56 (Suppl 7): 3944.
  • Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen, Kwon JM, Wu W, Dick DM, Rice J, Jones K, Nurnberger JI Jr., Tischfield J, Porjesz B, Edenberg HJ, Hesselbrock V, Crowe R, Schuckit M, Begleiter H, Reich T, Goate AM, Bierut LJ (2004) Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet 13:19031911.
  • Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang BZ, Krupitsky E, Zvartau E, Gelernter J (2006) Association between two μ opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet 15:807819.
  • Zhang Y, Wang D, Johnson AD, Papp AC, Sadée W (2005) Allele expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280:3261832624.